Literature DB >> 8800627

Dose-related adverse effects of anticonvulsants.

A S Troupin1.   

Abstract

The serum concentration at which a given drug has full efficacy in delivering seizure control bears no predictable relationship to the concentration at which adverse effects will appear. In theory, the threshold for adverse effects should be considerably higher than that for efficacy. For each agent this obviously happens most of the time, or the anticonvulsant would not be on the market, but there are also patients in whom this relationship is reversed. The adverse effects of this class of drugs are discussed from three points of view: the adverse effect type, the kinetic factors that so frequently determine the presence of adverse effects, and the specific characteristics of each drug. Some less well recognized adverse effects syndromes that are not strictly dose related are considered. The importance of adverse effects in therapeutic monitoring is then addressed, and some strategies for maximising efficacy without the burden of long term functional impairment or distress are discussed. The usefulness of monotherapy is stressed with due attention to rational choice of second drugs, when necessary, based on mechanisms of antiepileptic action and adverse effects profiles. While most of these symptoms evolve gradually, there are times when acute, drastic, and even life threatening clinical overdose situations present themselves. Special attention is given to these scenarios, drawing on the drug profiles and clinical pharmacokinetics that define these events to propose methods of coping with the problems efficiently and effectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800627     DOI: 10.2165/00002018-199614050-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  40 in total

1.  Controlled trial of sodium valproate in severe epilepsy.

Authors:  A Richens; S Ahmad
Journal:  Br Med J       Date:  1975-11-01

2.  Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.

Authors:  U Klotz
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-01

3.  Conjugate lateral gaze nystagmus and free phenytoin concentrations in plasma: lack of correlation.

Authors:  W K Riker; H Downes; G D Olsen; B Smith
Journal:  Epilepsia       Date:  1978-02       Impact factor: 5.864

Review 4.  Gabapentin.

Authors:  M J McLean
Journal:  Epilepsia       Date:  1995       Impact factor: 5.864

5.  Carbamazepine and serum sodium levels.

Authors:  R Kalff; M A Houtkooper; J W Meyer; D M Goedhart; R Augusteijn; H Meinardi
Journal:  Epilepsia       Date:  1984-06       Impact factor: 5.864

6.  Treatment of valproate tremors.

Authors:  B J Karas; B J Wilder; E J Hammond; A W Bauman
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

Review 7.  Clinical uses of the quality-of-life in epilepsy inventory.

Authors:  O Devinsky
Journal:  Epilepsia       Date:  1993       Impact factor: 5.864

8.  Displacement of phenytoin from plasma binding sites by salicylate.

Authors:  D G Fraser; T M Ludden; R P Evens; E W Sutherland
Journal:  Clin Pharmacol Ther       Date:  1980-02       Impact factor: 6.875

9.  Asymptomatic hyperammonemia in patients receiving valproic acid.

Authors:  J V Murphy; K Marquardt
Journal:  Arch Neurol       Date:  1982-09

10.  Sodium valproate "encephalopathy": report of three cases with generalised epilepsy.

Authors:  A Tartara; R Manni
Journal:  Ital J Neurol Sci       Date:  1985-03
View more
  3 in total

Review 1.  The tolerability of lamotrigine in children.

Authors:  J A Messenheimer; L Giorgi; M E Risner
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

2.  The tolerability of lamotrigine in elderly patients with epilepsy.

Authors:  L Giorgi; G Gomez; F O'Neill; A E Hammer; M Risner
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  DNA damage by Withanone as a potential cause of liver toxicity observed for herbal products of Withania somnifera (Ashwagandha).

Authors:  Shazia Siddiqui; Nabeel Ahmed; Mausumi Goswami; Anindita Chakrabarty; Goutam Chowdhury
Journal:  Curr Res Toxicol       Date:  2021-02-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.